Excellent
Fully Aligned
Patient Risk:
Low
Summary
The AI claim is fully supported by the FDA label: it describes behavioral abnormalities/psychotic symptoms and specifically includes irritability and aggression with monitoring and counseling language.
Category Scores
Accurate Statements
Levetiracetam extended-release tablets can cause behavioral and neuro/psychiatric changes, including irritability and aggression.
Supported by Label 5.1 (behavioral abnormalities and psychotic symptoms; monitoring psychiatric signs/symptoms) and Label 5.1 incidence data (irritability 7%, aggression 1% vs placebo 0%); reinforced by Label 17 patient counseling (changes in behavior e.g., irritability and aggression).
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The AI statement is an accurate, label-supported description of potential neuropsychiatric/behavioral effects, and does not add off-label specifics or incorrect risk information.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement